793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Lorusso, D., Mirza, M.R., Martin-Babau, J., Bologna, A., Barretina Ginesta, M.P., Marmé, F., Wampfler, J., Cibula, D., Zhu, J., Hasegawa, K., Samouëlian, V., Lee, J-Y., Casarotto, F.C., Antill, Y., Lightfoot, M., Herzog, T.J., Woodhouse, K., Cui, Y., Slomovitz, B.M., Monk, B.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Van Gorp, T., Rob, L., Lu, W., Backes, F., Ortaç, F., Hasegawa, K., Hietanen, S.H., Savarese, A., Laenen, A., Kim, Y.M., Bodnar, L., Barretina Ginesta, M.P., Gilbert, L., Pothuri, B., Chen, X., Lichfield, J., Wang, W., Orlowski, R.J., Lortholary, A., Slomovitz, B.M.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
González-Martín, A., Pothuri, B., Barretina Ginesta, M.P., Graybill, W.S., Vergote, I.B., McCormick, C., Mirza, M.R., Moore, R.G., Lorusso, D., O'Cearbhaill, R.E., Freyer, G., O'Malley, D.M., Heitz, F., Shahin, M.S., Bruchim, I., Bradley, W.H., Compton, N., Malinowska, I., Redondo, A., Monk, B.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Gonzalez Martin, A., Rubio Perez, M.J., Heitz, F., Christensen, R.D., Colombo, N., Van Gorp, T., Oaknin, A., Leary, A., Gaba Garcia, L., Lebreton, C., De Sande González, L.M., Romeo Marin, M., Redondo, A., Barretina Ginesta, M.P., Perez Fidalgo, J.A., Santaballa Bertran, A., Bermejo-Pérez, M.J., Bruchim, I., Ray-Coquard, I.L., Selle, F.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
Colombo, N., Harano, K., Hudson, E., Galli, F., Antill, Y., Choi, C.H., Rabaglio, M., Marmé, F., Petru, E., Lai, C-H., Biagioli, E., Fariñas Madrid, L., Takehara, K., Allan, K., Lee, Y.C., Piovano, E., Zamagni, C., Tasca, G., Ferrero, A., Barretina Ginesta, M.P.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
Colombo, N., Antill, Y., Barretina Ginesta, M.P., Harano, K., Hudson, E., Marmé, F., Marth, C., Rabaglio, M., Secord, A.A., Fossati, R., Roberto, A., Tettamanzi, F., Biagioli, E.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee
Woopen, H., Sehouli, J., Davis, A., Lee, Y.C., Cohen, P.A., Ferrero, A., Gleeson, N., Jhingran, A., Kajimoto, Y., Mayadev, J., Barretina-Ginesta, M.P., Sundar, S., Suzuki, N., van Dorst, E., Joly, F.
Published in Cancer treatment reviews (01.06.2022)
Published in Cancer treatment reviews (01.06.2022)
Get full text
Journal Article
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Monk, B.J., Barretina-Ginesta, M.P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M.R., McCormick, C.C., Lorusso, D., Moore, R.G., Freyer, G., O’Cearbhaill, R.E., Heitz, F., O’Malley, D.M., Redondo, A., Shahin, M.S., Vulsteke, C., Bradley, W.H., Haslund, C.A., Chase, D.M., Pisano, C., Holman, L.L., Pérez, M. J. Rubio, DiSilvestro, P., Gaba, L., Herzog, T.J., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I.A., González-Martín, A.
Published in Annals of oncology (01.11.2024)
Published in Annals of oncology (01.11.2024)
Get full text
Journal Article
880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
Oaknin, A., Iglesias, M., Alarcon, J.D., Villacampa Javierre, G., Garcia, L. Gaba, Santaballa, A., Manso, L.M., Romero, I., Barretina Ginesta, M.P., Churruca, C., García, Y., Sanchez, A.B., Marquina, G., Pardo, B., Redondo, A., Rubio, M.J., González Martín, A.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)
Plaja Salarich, A., Teruel García, I., Pardo Burdalo, B., Gil-Martin, M., Piulats, J.M., Fina Planas, C., Barretina Ginesta, M.P., Ferrando Diez, A., Notario Rincon, L., Pous Badia, A., Gonzalez Valencia, A., Esteve Gomez, A., Romeo Marin, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396]
Woopen, H., Sehouli, J., Davis, A., Lee, Y.C., Cohen, P.A., Ferrero, A., Gleeson, N., Jhingran, A., Kajimoto, Y., Mayadev, J., Barretina-Ginesta, M.P., Sundar, S., Suzuki, N., van Dorst, E., Joly, F.
Published in Cancer treatment reviews (01.09.2022)
Published in Cancer treatment reviews (01.09.2022)
Get full text
Journal Article
864P Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer
Leary, A., Estévez-García, P., Sabatier, R., Fariñas-Madrid, L., Pérez-Fidalgo, J.A., Romeo, M., Barretina Ginesta, M.P., Gil-Martin, M., Garralda, E., Rodon, J., Lizcano, J.M., Muñoz Guardiola, P., Pérez-Montoyo, H., Yeste-Velasco, M., Cortal, M., Domènech, C., Alfon, J., Ray-Coquard, I.L., Oaknin, A.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
Mirza, M.R., Bjørge, L., Marmé, F., DePont Christensen, R., Gil-Martin, M., Auranen, A., Ataseven, B., Rubio, M.J., Salutari, V., Lund, B., Runnebaum, I., Redondo, A., Lindemann, K., Trillsch, F., Barretina Ginesta, M.P., Roed, H., Løhndorf, J., Nyvang, G-B., Sehouli, J.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
35MO Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Ginesta, M.P. Barretina, Uggeri, S., Harano, K., Galli, F., Hudson, E., Antill, Y., Kim, S.W., Rabaglio, M., Braicu, I., Berger, R., Lin, H., Baldini, E., Redondo, A., Takehara, K., Allan, K., Lee, Y.C., Palaia, I., Casanova, C., Villa, F., Colombo, N.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)
España Fernandez, S., Piulats, J.M., Sala, N., Velarde, J.M., Ferrandiz, U., Etxaniz Ulazia, O., Heras Lopez, L., Barretina Ginesta, M.P., Garcia del Muro, X., Font, A.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
36MO Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 trial
Lee, Y.C., Colombo, N., Harano, K., Rulli, E., Hudson, E., Lee, K.B., Rabaglio, M., Braicu, I., Petru, E., Ou, Y-C., Biagioli, E., Redondo, A., Takehara, K., Allan, K., Antill, Y., Lapresa, M., Piovano, E., Tasca, G., Zamagni, C., Ginesta, M.P. Barretina
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
51P Efficacy and safety by time to maintenance therapy treatment initiation in PRIMA/ENGOT-OV26/GOG-3012
Haslund, C.A., Willmott, L.J., Pérez, M.J. Rubio, Cloven, N., Van den Bulck, H.F.M., Moore, R.G., Pisano, C., O'Cearbhaill, R.E., Selle, F., Pothuri, B., Harter, P., Ghamande, S., Bruchim, I., Disilvestro, P., Ginesta, M.P. Barretina, Koliadi, A., Malinowska, I., York, W., González-Martín, A., Monk, B.J.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy
Mesía, R., Majem, M., Barretina Ginesta, M.P., Galiana, R., Mañós, M., Guedea, F., Montes, A., Monner, A., Pérez, J., Cardenal, F.
Published in Cancer radiothérapie (01.03.2008)
Published in Cancer radiothérapie (01.03.2008)
Get full text
Journal Article